Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Merck
Johnson and Johnson
Express Scripts
Moodys

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Litigation Details for TARO PHARMACEUTICALS U.S.A., INC. v. GLENMARK PHARMACEUTICALS LTD. (D.N.J. 2018)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

TARO PHARMACEUTICALS U.S.A., INC. v. GLENMARK PHARMACEUTICALS LTD. (D.N.J. 2018)

Docket   Start Trial Date Filed 2018-08-08
Court District Court, D. New Jersey Date Terminated
Cause 35:271 Patent Infringement Assigned To John Michael Vazquez
Jury Demand None Referred To Mark Falk
Parties GLENMARK PHARMACEUTICALS INC., USA; GLENMARK PHARMACEUTICALS LTD.; TARO PHARMACEUTICALS NORTH AMERICA, INC.; TARO PHARMACEUTICALS U.S.A., INC.
Patents 8,277,780; 8,715,624
Attorneys GENE Y. KANG; GREGORY D. MILLER; JENNA Z. GABAY; MELISSA E. FLAX; MICHAEL CROSS
Firms Carella, Byrne, Cecchi, Olstein, Brody & Agnello, P.C.; Carella, Byrne, Cecchi, Olstein, Brody & Agnello, PC; Rivkin Radler LLP
Link to Docket External link to docket
Small Molecule Drugs cited in TARO PHARMACEUTICALS U.S.A., INC. v. GLENMARK PHARMACEUTICALS LTD.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for TARO PHARMACEUTICALS U.S.A., INC. v. GLENMARK PHARMACEUTICALS LTD. (D.N.J. 2018)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 1 Complaint infringement of United States Patent Nos. 8,277,780 (the “’780 patent”) (attached as Exhibit A) and …must include, among other things, the patent number of any patent that claims the drug or a method of … Taro’s Patents Covering Topicort® 27. The United States Patent & Trademark Office…the ’780 and ’624 patents with the FDA. The FDA has published the ’780 and ’624 patents in the Orange Book…expiration of the ’780 patent will constitute an act of infringement of the ’780 patent. 39. On External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Johnson and Johnson
McKinsey
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.